Standard BioTools
LAB
81 hedge funds and large institutions have $217M invested in Standard BioTools in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 11 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
19% more capital invested
Capital invested by funds: $182M → $217M (+$35.1M)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
1% more funds holding
Funds holding: 80 → 81 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less call options, than puts
Call options by funds: $283K | Put options by funds: $300K
28.09% less ownership
Funds ownership: 123.1% → 95.01% (-28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$2.54M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$2.1M |
| 3 |
BlackRock
New York
|
+$1.85M |
| 4 |
AC
Alexandria Capital
Arlington,
Virginia
|
+$1.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$759K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.54M |
| 2 |
Neuberger Berman Group
New York
|
-$2.56M |
| 3 |
O
OrbiMed
New York
|
-$889K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$538K |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$391K |
LAB Hedge Fund Activity: Q4 2017 in Review
81 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2017, worth a combined $217M — up 19% from $182M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LAB positions and 11 closed out — a net gain of 2 holders — while 34 added to existing stakes and 22 trimmed.
The largest buyer was Levin Capital Strategies, adding an estimated $2.54M. The largest seller was Adage Capital Partners, cutting an estimated $3.54M.
- 81 institutional investors held Standard BioTools (LAB) as of Q4 2017, up from 80 in Q3 2017.
- Funds reported $217M of Standard BioTools stock for Q4 2017, up 19% quarter-over-quarter.
- 13 funds opened new Standard BioTools positions in Q4 2017 and 11 closed out, a net change of +2 holders.
- The largest Standard BioTools buyer in Q4 2017 was Levin Capital Strategies, an estimated $2.54M added.
- The largest Standard BioTools seller in Q4 2017 was Adage Capital Partners, an estimated $3.54M sold.
Based on aggregated 13F filings for Q4 2017.